Drug profile · INN
colistimethate sodium
COLOBREATHE
colistimethate sodium (COLOBREATHE) is a cell membrane inhibitor. Associated with Essential Pharma Limited. Route of administration: injection. Current US regulatory status: approved.
Drug details — colistimethate sodium
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- INJECTION
- Patents
- 20
- Programs
- 1
- Data quality
- 0.89
Quick answer
colistimethate sodium (COLOBREATHE) is a cell membrane inhibitor. Associated with Essential Pharma Limited. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Cell membrane inhibitor
Primary target: Cell membrane
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 11786536
Salts of potassium ATP channel openers and uses thereof
granted -
US 11786524
Pharmaceutical compounds
granted -
US 11690933
Absorbent aliphatic polyurethane foam product
granted -
US 11445997
Ultrasound imaging of biomarker sensitive hydrogels
granted -
US 11273191
Administering compositions for improved immune system functioning
granted -
US 11045478
Salts of potassium ATP channel openers and uses thereof
granted -
US 10973817
Pharmaceutical compounds
granted -
US 10874676
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 10702590
Compositions and methods for treating thyroid disease
granted -
US 10456408
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 10105289
Biomimetic mineral based endodontic cement composition and uses thereof
granted -
US 10098379
Device and method for simulating chemosensation of smoking
granted -
US 10085998
Salts of potassium ATP channel openers and uses thereof
granted -
US 10058557
Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
granted -
US 9765043
Salts of potassium ATP channel openers and uses thereof
granted -
US 9381202
Salts of potassium ATP channel openers and uses thereof
granted -
US 9211277
Dietary supplement composition
granted -
US 8765933
Asynthesis of β-nucleosides
granted -
US 8716287
Pharmaceutical compounds
granted
Frequently asked questions
What is colistimethate sodium?
colistimethate sodium (COLOBREATHE) is a cell membrane inhibitor. Associated with Essential Pharma Limited. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for colistimethate sodium?
COLOBREATHE is a marketed brand name for colistimethate sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of colistimethate sodium?
colistimethate sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.